Nucala (Mepolizumab)

Save over 50% on Nucala pens today.  Product of Europe by GlaxoSmithKline.

Nucala is shipped by cold chain from our pharmacy in India.

Manufacturer for all European Nucala: GlaxoSmithKline Manufacturing S.P.A Strada Provinciale Asolana, No 90 43056 San Polo di Torrile, Parma Italy

Information about Nucala (Mepolizumab)

Nucala (generic name: mepolizumab) is a prescription medication that is used to treat certain types of severe asthma and other eosinophilic disorders. It is a monoclonal antibody that targets and inhibits interleukin-5 (IL-5), a key protein that plays a central role in the activation and survival of eosinophils, which are white blood cells involved in inflammatory processes. By reducing eosinophil levels, Nucala helps to decrease inflammation and improve symptoms in individuals with conditions like asthma.

Product Highlights

• Nucala is approved for the treatment of severe asthma in patients with high levels of eosinophils (eosinophilic asthma) who have not responded adequately to other treatments.
• Nucala is used as an add-on therapy for the treatment of EGPA, a rare autoimmune disease.
• It is indicated for the treatment of CRSwNP in adults who have inadequate response to other therapies.
• It may be used for the treatment of hypereosinophilic syndrome, a condition characterized by high levels of eosinophils causing damage to organs.

Key Ingredient

• Mepolizumab 

Key Benefits

• Nucala significantly reduces the frequency of asthma exacerbations in patients with eosinophilic asthma.
• It helps in improving lung function and reducing the need for oral corticosteroids in patients with severe asthma.
• By targeting eosinophils, Nucala helps reduce the inflammation associated with eosinophilic disorders like asthma and EGPA.
• Subcutaneous injections can be administered by patients at home, allowing for flexible treatment schedules once a healthcare provider confirms the patient is trained in self-injection.

Direction of Use

• Nucala is typically administered once every 4 weeks as a subcutaneous injection. The injection can be administered in the upper arm, thigh, or abdomen.
• The dosing schedule may differ based on the specific condition and medical guidelines, and it is important to follow the healthcare provider's instructions.
• Patients can be trained to administer the injection themselves after consultation with their healthcare provider, but it should only be done under medical supervision initially.

Safety Concerns

• As with any monoclonal antibody, there is a risk of severe allergic reactions, including anaphylaxis. Patients should be monitored for at least 1 hour after the first few injections.
• Nucala may increase the risk of infections, particularly respiratory tract infections, and should be used with caution in patients with ongoing infections.
• There may be an increased risk of herpes zoster infections (shingles), and patients should be monitored for signs of viral infections.
• As Nucala can decrease eosinophil counts, it may increase the risk of certain parasitic infections. It's important to screen for parasitic infections before starting therapy.
• Some patients may experience hypersensitivity reactions such as rash, itching, or swelling.

Avoid Nucala (Mepolizumab) If

• Do not use if there is a known allergy to mepolizumab or any of the ingredients in the formulation.
• Nucala should not be used in patients with active, untreated infections, including severe systemic infections, as it could worsen the infection or interfere with immune function.
• The safety of Nucala during pregnancy and breastfeeding is not fully established. It should only be used during pregnancy if the potential benefits exceed the potential risks to the fetus.
• Caution should be used when administering live vaccines in patients taking Nucala due to potential immune suppression.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.